Boyalife Group Ltd., together with its subsidiaries and companies consolidated for accounting purposes, is a leading provider of biotechnology services in China.
The directors of Boyalife Group recognize the need to conduct the business of the Group with integrity and in accordance with suitable governance practices.
The requisite improvements to the Group’s corporate governance procedures and policies have either been implemented or are in the process of being implemented.
Boyalife is governed by a unitary board of directors which has established the following sub-
- Audit Committee
- Corporate Governance Committee
- Investment Committee
- Nomination Committee
- Remuneration Committee
Each committee acts within agreed terms of reference.
For retail investors, institutional investors, analysts and financial media